AK104 to prevent HCC coming back after surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (HCC) confirmed by pathology, and it has not spread to other organs.
- You had curative (complete) surgery as the only cancer treatment, with no leftover cancer seen during or after the operation.
- You have at least one “high-risk” reason the cancer might come back after surgery.
- Your liver function is good (Child-Pugh A), and you are generally well enough to do usual activities (ECOG 0).
- You can have liver scans (enhanced CT or MRI) around the time of the study.
- You have controlled causes of HCC and no major medical issues like serious heart disease or active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs for people with advanced liver cancer that has progressed after first-line treatment. It aims to see if this combination can help control the cancer.
This trial tests if adding a new combination of drugs (AK104 and lenvatinib) to a standard liver cancer procedure called TACE is more effective than TACE alone. It is for people whose liver cancer has not spread and cannot be removed by surgery, but who are well enough to receive these treatments.
This trial is testing a new combination of drugs (an immunotherapy called AK104 plus a targeted therapy called lenvatinib) compared to lenvatinib alone, for people whose liver cancer has grown after they received the standard first-line treatment with atezolizumab and bevacizumab. The goal is to see if combining the two drugs can better control the cancer and help patients live longer.
This trial tests a new immunotherapy drug called AK112 for people with advanced liver cancer that hasn't spread to the brain or key blood vessels. It may be an option if you haven't had immunotherapy before and your liver is still working well.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.